Class IIOngoingD-0341-2024
Drug recall · February 28, 2024
Terlivaz recall
Why: cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Terlivaz (terlipressin for injection), 0.85mg/vial, Single-Dose Vial, Rx only, Distributed by: Mallinckrodt Hospital Products Inc., Bridgewater, NJ 08807, USA, NDC 43825-200-01
- Lots / codes
Lot #: 22TRP01-F2, Exp 6/30/2024
- Quantity
- 421 vials involved in this recall (2,448 vials distributed)
- Company
- Mallinckrodt Hospital Products Inc., Bridgewater, NJ
- Distribution
- USA nationwide
- Initiated
- February 6, 2024 · Voluntary: Firm initiated
- Classified
- February 21, 2024
- Reported
- February 28, 2024
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.